Brief: Arvinas Announces FDA Approval Of Veppanu For Treatment Of ESR1m, ER+/HER2- Advanced Breast Cancer
01/05/2026 18:11
May 1 (Reuters) - Arvinas Inc ARVN.O: ARVINAS ANNOUNCES FDA APPROVAL OF VEPPANU (VEPDEGESTRANT) FOR THE TREATMENT OF ESR1M, ER+/HER2- ADVANCED BREAST CANCER ARVINAS INC - FDA APPROVAL GRANTED BEFORE JUNE 5, 2026 PDUFA DATE ARVINAS INC - CO, PFIZER TO SELECT THIRD-PARTY PARTNER FOR VEPPANU COMMERCIALIZATION Source text: ID:nGNX4MPn6Q Further company coverage: ARVN.O ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Arvinas
See all newsBrief: Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Arvinas Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Arvinas - Pfizer, And Rigel Receive Hart-Scott-Rodino Clearance For License Agreement On June 11, 2026
Brief: Arvinas - Announces Re-Prioritization Of Portfolio Following Strategic Review - SEC Filing
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology